- ►nih.gov - Free from Publisher P Gæde, WJ Valentine, AJ Palmer, D Tucker, … - Diabetes Care, 2008 - Am Diabetes Assoc RESULTS—Intensive treatment was associated with increased life expectancy,
QALE, and lifetime costs compared with conventional treatment. Mean ± SD
undiscounted life expectancy was 18.1 ± 7.9 years with intensive treatment ... Cited by 18 - Related articles - All 5 versions
M MCCREDIE - Diabetic medicine, 2006 - cat.inist.fr Aims To describe the variation in geographical distribution of end-stage renal
disease(ESRD) due to Type 1 and Type 2 diabetes, and to calculate recent trends
in incidence in predominantly white populations. Methods Estimation of age- ... Cited by 2 - Related articles
PC Stafylas, PA Sarafidis, DM Grekas, AN … - Journal of Clinical Hypertension, 2007 - interscience.wiley.com The aim of this study was to estimate the cost-effectiveness of
renin-angiotensin-aldosterone system blockers in patients with diabetic
nephropathy. A cost-effectiveness analysis was performed based on a meta- ... Cited by 2 - Related articles - BL Direct - All 5 versions
MJ Postma, C Boersma, RT Gansevoort - Nephrology Dialysis Transplantation, 2008 - ERA-EDTA In this issue, Palmer et al. [1] demonstrate that screening for nephropathy in
hypertensive type 2 diabetic patients and subsequent treatment with
renoprotective antihypertensive agents may result in excellent value for ... Cited by 3 - Related articles - BL Direct - All 8 versions
AJ Palmer, WJ Valentine, JA Ray, S Roze, N … - The European Journal of Health Economics, 2007 - Springer Abstract To perform a health economic analysis on treatment with irbesartan in
patients with type 2 dia- betes and hypertension. A Markov model was adapted to
the Hungarian setting to simulate renal deterioration from the development ... Cited by 3 - Related articles - BL Direct - All 4 versions
L Jönsson, GW Carides, TA Burke, AS Brandt, … - Journal of Medical Economics, 2005 - informahealthcare.com A previous clinical trial (RENAAL) has demonstrated that co-administration of
losartan, an angiotensin-II-receptor antagonist, with existing conventional
antihypertensive therapy (CT) reduces the risk of development of end-stage ... Cited by 4 - Related articles - All 2 versions
AJ Palmer, S Roze, WJ Valentine, JA Ray, A … - Swiss Medical Weekly, 2006 - smw.ch Objectives: The aim of this health economic modelling study was to investigate
the effect of irbesartan combined with conventional antihyper- tensive
medications compared to conventional an- tihypertensive therapy alone on ... Cited by 5 - Related articles - View as HTML - BL Direct - All 3 versions
- ►giantt.nl [PDF] - Free from Publisher J Voorham, FM Haaijer-Ruskamp, RP Stolk, … - Diabetes care, 2008 - Am Diabetes Assoc Undertreatment of risk factors in patients with type 2 diabetes is common. We
assessed the influence of elevated levels of blood pressure, total cholesterol,
and A1C on decisions of Dutch general practitioners to change drug ... Cited by 4 - Related articles - BL Direct - All 7 versions
A Maione, A Nicolucci, JC Craig, G Tognoni, A … - Journal of nephrology, 2007 - jnephrol.com Microalbuminuria is a strong, consistent and independent risk factor for
cardiovascular and renal disease in patients with di- abetes and/or hypertension
and in the general population. Several randomized trials have shown the ... Cited by 4 - Related articles - View as HTML - BL Direct - All 4 versions
J Vora, G Carides, P Robinson - Current Therapeutic Research, 2005 - Elsevier In the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with
the Angiotensin II Antagonist Losartan (RENAAL) study, the primary composite end
point was the 2-fold increase in baseline serum creatinine concentration, ... Cited by 5 - Related articles - All 2 versions
